Navigation Links
Prana Biotechnology Presents New Key Findings on PBT2

ker protein synaptophysin.

The amyloid plaques which are the main pathological feature of the brains of Alzheimer's sufferers are composed of aggregates of the Abeta protein. The Alzheimer's research community largely supports the hypothesis that small, soluble, mobile aggregates (oligomers) of the Abeta protein are the cause of neurotoxicity in AD. PBT2's ability to inhibit the generation and toxicity of these oligomers, as well as preventing the hyperphosphorylation of tau, while improving cognition, supports the disease modifying potential of PBT2 and other drugs in the Prana development pipeline.

Geoffrey Kempler, Chairman and Chief Executive Officer of Prana commented: "The results of these studies are encouraging and lend further support to the theories driving development of PBT2. We continue to improve our understanding of PBT2's functionality and potential for disease modification as we move forward with formal clinical development. The ongoing PBT2 Phase IIa trial in early Alzheimer's patients is on track to complete dosing by the end of this year and report early in 2008."

The technique of in vivo brain microdialysis recently adopted as a research tool by Prana scientists provides a unique insight into a dynamic metabolic process, allowing researchers to sample secretions from the brains of conscious, unrestrained test animals freely interacting with their environment. Sampling from the brains of genetically-engineered AD mouse models which have received single or sequential oral doses of PBT2, it was found that the drug exerts its inhibitory effects upon the target molecule, Abeta, rapidly and reproducibly without causing "rebound" effects observed with other drugs in development. Most particularly, a dramatic reduction was observed in soluble oligomers of the size range identified in the literature as the most toxic form of Abeta amyloid in AD.

The findings of these studies confirm and expand upon data presented by the Compan
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
3. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
4. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
5. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting
6. Generex Biotechnology Vaccine Strategy Presented at International Conference in London
7. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at AUA Annual Meeting
8. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
9. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
10. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
11. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Prana Biotechnology Presents New Key Findings PBT2
(Date:7/28/2014)... , July 28, 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ... Second Quarter 2014 Financial Results and Highlights Conference CallWhen:Monday, ... PTWhere: www.isispharm.com How:Live on the Internet. Simply log ... to participate during the live event, a replay of ... at www.isispharm.com . ABOUT ISIS PHARMACEUTICALS, ...
(Date:7/28/2014)... -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) ... 2014 financial results on Monday, August 4, 2014, after ... announcement, members of the management team will host a ... a general corporate update at 4:30 p.m. EDT (1:30 ... as follows: Monday, August 4 1:30 ...
(Date:7/25/2014)... 25, 2014  In today,s marketplace, launching multiple products ... - as is managing a portfolio of products in ... possible - or even preferable - to pool resources ... you combine resources and activities, and what marketing and ... are just a few of the dilemmas facing pharmaceutical ...
Breaking Medicine Technology:Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2Using Promotional Efficiency to Support Multiple Products and Indications in the Pharmaceutical Marketplace 2
... , SAN DIEGO, Nov. 18 Rules-Based ... biomarker alliance and services agreement with Covance Inc. (NYSE: ... with a powerful combination of biomarker technologies and services for ... will use RBM as its exclusive third-party provider of multiplexed ...
... , NASHVILLE, Tenn., Nov. 17 Emdeon (NYSE: ... cycle management solutions, today announced that it will participate in the ... 1 to 2, 2009 in New York. , The "fireside chat", ... time on Tuesday, December 1, 2009. A live audio webcast ...
Cached Medicine Technology:Rules-Based Medicine Forms Biomarker Alliance With Covance Inc. 2Rules-Based Medicine Forms Biomarker Alliance With Covance Inc. 3
(Date:7/28/2014)... (PRWEB) July 28, 2014 The ... the majority of professionals engaged in the field ... the Transplantation and Immunology Research Network ... and immunology research. As modern organ transplantation continues ... network that could provide more opportunities for physicians, ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 At some point ... situation where they’re forced to contact the authorities. Distinguishing ... difficult than it initially seems. , Not every dangerous situation ... get stolen, a person get mugged, or a bank get ... obvious, leading onlookers to be more passive than they otherwise ...
(Date:7/28/2014)... University of Texas Health Science Center at San Antonio, the ... of pills that cures 9 of 10 hepatitis C patients. ... or without ribavirin, cured 93 percent of patients in 12 ... study published today in The Lancet . , ... Lawitz, M.D., clinical professor in the School of Medicine at ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, July 28, ... have a slightly increased risk of potentially fatal blood ... report. Doctors have previously suspected that babies born ... of deep vein thrombosis and pulmonary embolism, two serious ... researchers noted in background information. This new study ...
(Date:7/28/2014)... 2014A two-step decision tree analysis, incorporating Donabedian,s model, ... the many available quality standards, guidelines, recommendations and ... international quality standards for radiation therapy, according to ... of Practical Radiation Oncology (PRO), the ... for Radiation Oncology (ASTRO). , Guidelines, recommendations and ...
Breaking Medicine News(10 mins):Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 2Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 3Health News:Take Action To Protect Your Fellow Citizens 2Health News:Take Action To Protect Your Fellow Citizens 3Health News:New pill regimens published in The Lancet cure hardest-to-treat hepatitis C patients 2Health News:Preemies May Have Higher Risk of Blood Clots, Even as Adults 2Health News:Preemies May Have Higher Risk of Blood Clots, Even as Adults 3Health News:Two-step decision tree analysis helps inform updates of RT best practices, quality standards 2Health News:Two-step decision tree analysis helps inform updates of RT best practices, quality standards 3
... Consumer Watchdog sent a letter to Senator ... expressing their profound disappointment that consumer advocates had ... the Massachusetts senator to formulate health care reform ... recent national polls showing the public overwhelming opposed ...
... Results To Offer New Insights on How Well Asthma ... The American Lung Association of New England (ALANE) has ... offer an online survey and corresponding report that will ... being controlled and encourage them to discuss the results ...
... ROCKVILLE, Md., Feb. 20 /PRNewswire-Asia/ -- Synutra,International, ... a leading infant formula,company in China, and ... products,for infants, children and adults, today issued ... permit numbers in a published list of ...
... eFoodSafety.com, Inc., (OTC Bulletin Board: EFSF) an emerging ... aesthetics, dermatology, environmental and nutraceutical products, outlined its ... 30, 2010 during its regularly scheduled monthly investor ... eFoodSafety.com intends to increase revenues by improving the ...
... Many people seek answers to questions of motivation and ... by Justin Honaman employs lessons learned in his career ... an effort to help others direct their energies and ... chapters of "Make It Happen" that personal branding is ...
... the world,s largest autism science and advocacy organization, is teaming up ... series "Wow! Wow! Wubbzy!" - to promote World Autism Awareness Day ... autism as a worldwide health crisis. , ... New ...
Cached Medicine News:Health News:Consumer Watchdog to U.S. Senate: Don't Leave Consumers Out of Health Reform Debate, Public Opposes Mandatory Purchases of Private Insurance & Supports Opening Medicare to Everyone 2Health News:American Lung Association of New England Launches Online Asthma Control Test 2Health News:American Lung Association of New England Launches Online Asthma Control Test 3Health News:American Lung Association of New England Launches Online Asthma Control Test 4Health News:Synutra Issues Statement Regarding Market Rumors on Revocation of its Production Certification 2Health News:Synutra Issues Statement Regarding Market Rumors on Revocation of its Production Certification 3Health News:eFoodSafety.com Provides Revenue Guidance for FY 2010 2Health News:eFoodSafety.com Provides Revenue Guidance for FY 2010 3Health News:Business Strategist Applies Corporate Experience to Self-Help: 'Make It Happen' 2Health News:Autism Speaks and 'Wow! Wow! Wubbzy!' Team Up to Shine a Spotlight on World Autism Awareness Day 2Health News:Autism Speaks and 'Wow! Wow! Wubbzy!' Team Up to Shine a Spotlight on World Autism Awareness Day 3Health News:Autism Speaks and 'Wow! Wow! Wubbzy!' Team Up to Shine a Spotlight on World Autism Awareness Day 4
The FastPack system is a state of the art, lab quality immunoassay system designed for rapid results. The FastPack system delivers lab-quality sensitivity at a fraction of the cost of laboratory....
... When you need quick, accurate, convenient, and ... compact VITROS DT60 II Chemistry System. This ... and back-up laboratory testing requirements. And it ... -- better patient outcomes, reduced overall costs, ...
... In an effort to improve on ... hormones, toxicology, abused drugs, and immunosuppressants ... 1991 which incorporates random access capabilities. ... has undergone several important changes in ...
AxSYM Plus provides cutting-edge ergonomics and smart new features that mean increased ease-of-use and enhanced reliability. Also, advanced software means less operator intervention and high-integrit...
Medicine Products: